Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 5, 2020updated 06 Mar 2020 8:11am

Heat Biologics launches programme to develop vaccine against Covid-19

Heat Biologics, a clinical-stage biopharmaceutical company, has commenced a programme within its fully-owned subsidiary, Zolovax, to develop a vaccine using its gp96 vaccine platform for fighting Covid-19.

Heat Biologics, a clinical-stage biopharmaceutical company, has commenced a programme within its fully-owned subsidiary, Zolovax, to develop a vaccine using its gp96 vaccine platform for fighting Covid-19.

It has filed a provisional patent for use of its technology platform for treating Covid-19.

gp96 is a heat shock protein found in all human cells. It functions as a potent immune adjuvant that serves as “molecular warning system” to induce immunity against necrotic cells.

Naturally, gp96 is tethered to the cell and is normally released only during necrosis or cell death.

This vaccine platform reprogrammes live cells to continually secrete antigens bound to the gp96, thereby activating a strong T-cell response against those antigens.

Heat Biologics CEO Jeff Wolf said: “gp96 is a powerful vaccine platform that has been shown to induce a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models. We believe this platform has the potential to provide broad protection against COVID-19, and possible future mutations of COVID-19 or other coronaviruses. We look forward to providing further updates on our progress as developments unfold.”

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

The gp96 platform has undergone stringent testing in several National Institutes of Health (NIH) and US Department of Defense (DOD)-funded mice and primate trials as a vaccine against SIV/HIV, malaria, zika and other infectious diseases.

It has also been tested in more than 250 patients in multiple NIH and Heat-funded oncology trials.

 

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU